Fig. 8.

Simulated insulin degludec (IDeg) concentration–time profiles at steady state in smaller children (1–5 years), children (6–11 years), adolescents (12–17 years) and adults (18–65 years) over a 24-h dosing interval. The simulation was made using the final model from a joint analysis of the pharmacokinetic data from a single-dose trial with IDeg in children, adolescents and adults with type 1 diabetes mellitus (N = 36) [29] and steady-state population pharmacokinetic data obtained over 26 weeks in a clinical trial with IDeg in children and adolescents with type 1 diabetes (N = 169) [40]. The profiles shown are (median) for a typical subject in each age group [with body weight (BW) equal to the median BW in that age group]